AKBA - Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference

PR Newswire

CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- Akebia Therapeutics ^® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will participate in a fireside chat at the 2 ^nd Annual HCW Bioconnect Investor Conference on Monday, May 20 ^th , 2024 at 3:00 p.m. ET .

The 2 ^nd Annual HCW Bioconnect Investor Conference will take place in New York, NY on May 20, 2024 .

A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for 30 days following the conference.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts . For more information, please visit our website at www.akebia.com , which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

SOURCE Akebia Therapeutics, Inc.